-
Shionogi Joins the World Economic Forum and Signs the Davos Compact on Antimicrobial Resistance — Contributing to the Resolution of Global Healthcare Challenges, Including AMR, Through International Collaboration
-
Shionogi Receives Contract with U.S. Government Through BARDA’s Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats
-
SHIONOGI Group’s Efforts to Address AMR Highly Rated — Ranked No. 2 Among Global R&D-Based Pharmaceutical Companies in the Antimicrobial Resistance Benchmark 2026
-
Shionogi Awarded the Minister of Health, Labour and Welfare Award for Cefiderocol at the 8th Japan Medical Research and Development Grand Prize
-
Approval for Cefiderocol in China
-
Shionogi Pharma’s Kanegasaki Plant Receives “BSI Kitemark™ for Minimized Risk of AMR” Certification for Antimicrobial Manufacturing
-
IDWeek 2025: Shionogi Presents Real-World and Surveillance Data Reinforcing Role of Cefiderocol Across Range of Patient Populations and Difficult-to-Treat Infections
-
Gareth Morgan Named President of Qpex Biopharma, Inc.
-
Shionogi Highlights Japan’s Role in Advancing Global Health in Dialogue With Bill Gates — Discussing the Fight Against Infectious Diseases and the Future of Sustainable Healthcare Models Under the Theme “Japan’s Role in Advancing Global Health Progress”
-
Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek